In vitro fertilization (IVF) is a complex series of procedures used to treat fertility or genetic problems associated with fertility and assist with child conception. During IVF, mature eggs are collected (retrieved) from the ovaries and fertilized by the sperm cell in a laboratory, followed by the implantation of the fertilized egg (embryo) or eggs in the uterus. The Russia IVF market accounted for $398 million in 2015, and is estimated to reach at $641 million by 2022, registering a CAGR of 7.0% from 2016 to 2022.

IVF is a popular treatments that aids couples with infertility problems, single mothers, and the LGBT community to procreate. The Russia IVF market is expected to witness a substantial growth rate in the future, owing to high incidence of infertility cases, emergent trend of delayed pregnancies among women, technological developments in IVF procedures, and increased incidence of gamete donations.

Growth of the market is further augmented by the low-cost clinical settings for IVF treatments in comparison to U.S., UK, and other established markets. Popularity of Russia for medical tourism, owing to advanced IVF facilities and treatment options, supplement the market growth. However, poor reimbursement policies associated with IVF treatment are anticipated to impede the market growth during the forecast period. Furthermore, rise in concern of single parents and same-sex couples in experiencing parenthood through artificial reproductive technology (ART), especially IVF, is expected to present numerous opportunities for market expansion.

The Russia IVF market is segmented based on end user, cycle type, type, drug, and mode of administration. Based on end user, it is divided into fertility clinics, hospitals, surgical centers, and clinical research institutes. The cycle type is classified into fresh IVF cycles (non-donor), thawed IVF cycles (non-donor), and donor egg IVF cycles. Based on type, the market is bifurcated into non-ICSI IVF cycles and ICSI-assisted IVF cycles. On the basis of drug, it is classified into clomiphene citrate, aromatase inhibitors, gonadotropins & gonadotropin-releasing hormone, follicle-stimulating hormone, progesterone, and others. Mode of administration includes oral, injectable, and vaginal modes.


This report provides a detailed quantitative analysis of the current trends in the Russia IVF market from 2014 to 2022 to identify the prevailing opportunities.
Market estimations are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on drugs and end users assists to understand the market and the strategic business planning.
The developmental strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

By End User

Fertility Clinics
Surgical Centers
Clinical Research Institutes
By Cycle Type

Fresh IVF Cycles (Non-donor)
Thawed IVF Cycles (Non-donor)
Donor egg IVF Cycles
By Type

Non-ICSI IVF Cycles
ICSI-assisted IVF Cycles
By Drug

Clomiphene Citrate
Aromatase Inhibitors
Gonadotropins & Gonadotropin-releasing Hormone
Follicle-stimulating Hormone
By Mode of Administration


Ava-Peter Clinic
MD Medical Group
IVF Russia Agilent Technologies
The other players in the value chain include (profiles not included in the report):

Vitrolife AB
EMD Serono, Inc.
Irvine Scientific
Cooper Surgical, Inc.
Cook Medical, Inc.
Thermo Fisher Scientific, Inc.